Crossmark

Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis

Crossref DOI link: https://doi.org/10.1007/s10067-025-07651-1

Published Online: 2025-09-10

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aggarwal, Rohit https://orcid.org/0000-0001-7531-8038
Cai, Qian

Labson, Daniel

Crivera, Concetta

Zazzetti, Federico
Funding

Funding for this research was provided by:

This study was funded by Johnson & Johnson.
License Information

Text and Data Mining valid from 2025-09-10

Version of Record valid from 2025-09-10
More Information

Article History

Received: 6 February 2025

Revised: 31 July 2025

Accepted: 14 August 2025

First Online: 10 September 2025

Declarations

:

: RA has served as a consultant for Alexion, ANI Pharmaceuticals, argenx, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cabaletta Bio, Capella BioScience, Capstan, Corbus, CSL Behring, EMD Serono, Galapagos, Horizon Therapeutics, I-Cell, Immunovant, Janssen, Kezar, Kyverna, Lilly, Merck, Novartis, Nuvig Therapeutics, Octapharma, Pfizer, Roivant, Sanofi, and Teva; has received grant/research support from Boehringer Ingelheim, EMD Serono, Johnson & Johnson, Mallinckrodt, and Pfizer, and Q32; and has served in advisory boards for Johnson & Johnson. QC is a former employee of Johnson & Johnson. DL, CC, and FZ are employees and shareholders of Johnson & Johnson.

Document is current

Any future updates will be listed below